State Street SPDR S&P Biotech ETF vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.35, while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| XBI | XLY | |
|---|---|---|
Sector | Broad Market / Factor | — |
52-Week High | $164.28 | $124.52 |
52-Week Low | $86.92 | $105.64 |
Signals from Pluang's Aura AI — not financial advice
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
XLY trades at $117.89, down 1.49% today, but maintains a bullish technical outlook with strong moving average support. The ETF benefits from positive analyst sentiment with a 100% buy rating and recent coverage highlighting its potential as a 'sleeper ETF' for Q3 2026. Technical indicators show overbought conditions with RSI readings above 70, but the overall trend remains positive with key support at $118.
The consumer discretionary sector faces headwinds from inflation pressures, but XLY's diversified exposure positions it for recovery. Near-term risks include consumer spending sensitivity to economic conditions, while the bullish analyst consensus and technical momentum suggest potential upside if market conditions stabilize.
Trailing returns across standard periods
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →